HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing
Viruses · 2023
DOI: 10.3390/v15040992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Kaiming Tao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, HIV Seropositivity, Anti-HIV Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH/National Institute of Allergy and Infectious Diseases (NIAID).
Abstract (Originalsprache)
Background
With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia. Successful sequence interpretation will require examining new capsid sequences in the context of previously published sequence data.
Methods
We analyzed published HIV-1 group M capsid sequences from 21,012 capsid-inhibitor naïve individuals to characterize amino acid variability at each position and influence of subtype and cytotoxic T lymphocyte (CTL) selection pressure. We determined the distributions of usual mutations, defined as amino acid differences from the group M consensus, with a prevalence ≥ 0.1%. Co-evolving mutations were identified using a phylogenetically-informed Bayesian graphical model method.
Results
162 (70.1%) positions had no usual mutations (45.9%) or only conservative usual mutations with a positive BLOSUM62 score (24.2%). Variability correlated independently with subtype-specific amino acid occurrence (Spearman rho = 0.83; p < 1 × 10−9) and the number of times positions were reported to contain an HLA-associated polymorphism, an indicator of CTL pressure (rho = 0.43; p = 0.0002).
Conclusions
Knowing the distribution of usual capsid mutations is essential for sequence quality control. Comparing capsid sequences from lenacapavir-treated and lenacapavir-naïve individuals will enable the identification of additional mutations potentially associated with lenacapavir therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
- Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, PA 19122, USA.
- Department of Statistics, Stanford University, Stanford, CA 94305, USA.
ORCID-Profile: Kaiming Tao, Soo-Yon Rhee, Philip L Tzou, Sergei L Kosakovsky Pond, Robert W Shafer
Förderung
- NIAID NIH HHS
- NIH/National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Tao, K., Rhee, S. Y., Tzou, P. L., Osman, Z. A., Pond, S. L. K., Holmes, S. P., & Shafer, R. W. (2023). HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing. Viruses. https://doi.org/10.3390/v15040992
Vancouver
Tao K, Rhee SY, Tzou PL, Osman ZA, Pond SLK, Holmes SP, et al. HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing. Viruses. 2023. doi:10.3390/v15040992
BibTeX
@article{Tao2023,
author = {Tao, Kaiming and Rhee, Soo-Yon and Tzou, Philip L and Osman, Zachary A and Pond, Sergei L Kosakovsky and Holmes, Susan P and Shafer, Robert W},
title = {HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15040992}
}
EUVIMED